This site is intended for healthcare professionals only
LoginRegister
Biocon expects 50 percent drop in costs for developing complex biosimilars: Top executiveBiocon Biologics Bengaluru facility classified as VAI by USFDA
PharmEasy Slapped Rs 2 Lakh Fine for Auto-Add Subscription PracticePharmEasy Slapped Rs 2 Lakh Fine for Auto-Add Subscription Practice
DoP Shortlists Patented, Unlaunched Drugs for Global Tender Exemption, See Full ListDoP Shortlists Patented, Unlaunched Drugs for Global Tender Exemption, See Full List
Intas PharmaIntas Pharma Gets CDSCO Panel Nod to Conduct Phase I Trial of Pertuzumab, Trastuzumab Solution for...
Macleods Founder Dr Rajendra Agarwal No MoreFrom Jaipur Pharmacy to Global Pharma Leader: Pioneer of Affordable TB Medicines, Macleods Founder...
AstraZeneca Imfinzi gets USFDA okay for early gastric and gastroesophageal cancersAstraZeneca Imfinzi gets USFDA okay for early gastric and gastroesophageal cancers
Zydus Lifesciences strikes deal with RK Pharma for novel oncology supportive care injectableZydus Lifesciences strikes US licensing deal with RK Pharma for novel oncology supportive care...
Eris Lifesciences to buy balance 30 percent stake in Swiss Parenterals for Rs 423.3 croreEris Lifesciences to buy balance 30 percent stake in Swiss Parenterals for Rs 423 crore
CDSCO Panel Recommends Updating Prescribing Information for Sanofis VaccineSanofi-Regeneron Dupixent approved in EU for chronic spontaneous urticaria
India well positioned to evolve as innovation led pharma nation over next 5 years: CDSCOIndia well positioned to evolve as innovation led pharma nation over next 5 years: CDSCO
Bristol Myers Squibb Breyanzi secures European Commission nod for Mantle Cell LymphomaBristol Myers Squibb Breyanzi secures European Commission nod for Mantle Cell Lymphoma
CDSCO Flags 5 Batches of Widely Used Drugs Including Azithral-500, Telma-AM as Potentially SpuriousCDSCO Flags 5 Batches of Widely Used Drugs Including Azithral-500, Telma-AM as Potentially Spurious
X